Immunis Inc., an Irvine, CA-based biotechnology company developing a novel treatment for age and disease-related immune decline, raised $10M in Series A First Closing financing.
The round was led by Remiges Ventures with participation from several other healthcare investment firms.
The company intends to use the funds to support clinical assessment of its immunomodulatory secretome product in an FDA-awarded Phase 1/2a clinical trial targeting muscle atrophy, which is an age, disuse and disease-associated condition experienced by 100% of the population.
Immunis is a private biotechnology company developing a novel immunomodulatory secretome product for the various manifestations of age and disease-related immune decline. The STEM product line leverages capabilities in stem cell technology to deliver all natural, all human immune modulators in their natural, relative physiological concentrations.
Immunis’ unique secretome treatment, IMM01-STEM, addresses both medical needs using natural immunomodulators with potent cytoskeletal remodeling properties.
FinSMEs
04/08/2022